BioSpace News Archive

The patents are assigned to the University of California and licensed exclusively to Xona.

The two hires both have more than 20 years of experience in the field of cell therapy.

The Gluco-Chaser offers flexibility in choosing a platform format, cost savings in production and storage (highly affordable end user pricing), and other technical features that improve user comfort level and hygiene.

Therapix has received positive media coverage in a variety of financial and trade media outlets.

QuVa Pharma is currently supplying these products to existing customers and welcomes new inquiries.

The blueprint is already in production at leading sites such as Novant Health analyzing machine logs and providing proactive and predictive analytics.

The two leaders will combine tools aimed at reducing complexity and burden while improving outcomes in diabetes management.

he proof of concept study, including 404 patients, provides evidence for using DiviTum as a dynamic biomarker before and during therapy to give important answers regarding prognosis and how effective therapy is.

The PSORIXA study, MTI-109, is a multi-center, randomized, placebo-controlled study evaluating the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus associated with psoriasis.

Specifically, Fujifilm has secured contracts with two large providers in Arizona and the number one pediatric hospital in the U.S., Boston Children’s Hospital, for installations of various products from its comprehensive Synapse Enterprise Imaging portfolio including Synapse VNA, Synapse RIS, as well as solutions from the Synapse Cardiovascular portfolio.